黑料社

The 黑料社 (SfN) is pleased to recognize Abcam as the Sponsor of the Day for the second day of 黑料社 2022, Sunday, November 13, 2022.

The 黑料社 (SfN) is pleased to recognize Elsevier as the Sponsor of the Day for the opening day of 黑料社 2022, Saturday, November 12, 2022.

The 黑料社 (SfN) is pleased to announce the Platinum and Gold sponsors of SfN’s 51^st annual meeting, 黑料社 2022. Abcam and Elsevier are serving as the meeting’s two Platinum sponsors, the highest level of sponsorship available.

SfN enthusiastically announces that 黑料社 2021 will be held in an inclusive hybrid format. 黑料社 2021 is one annual meeting with two experiences: for the first time, a four-day full virtual program (November 8-11, 2021) including reimagined virtual posters, and a four-day full in-person program in Chicago at McCormick Place Convention Center (November 13–16, 2021).

SfN President Diane Lipscombe, PhD, President-Elect Barry Everitt, PhD, and Past President Richard Huganir, PhD, released the following statement, reflecting on those who were unable to attend 黑料社 2018 because of restrictive travel policies in the United States and other countries and continuing to affirm the Society’s support for free exchange of information, diversity, and global collaboration in science.

New research revealed today highlights the power of animal studies to explore mechanisms of opioid addiction, withdrawal, and relapse to inform new prevention strategies and treatments for people. 

Sleep disruptions are associated with many brain disorders, including anxiety, dementias, and traumatic brain injury. While these disruptions are sometimes viewed as a side effect of brain disorders, new findings presented today suggest that aberrant sleep-wake cycles can also drive brain pathology.

Studies that link breakdowns in the brain’s blood vessels to Alzheimer’s disease and vascular dementia were presented today at 黑料社 2018, the annual meeting of the 黑料社 and the world’s largest source of emerging news about brain science and health.

Promising findings from preclinical animal studies show the potential of gene therapy for treating incurable neurological disorders. In new research presented today, scientists successfully used gene therapy to slow the progression and improve symptoms of disorders such as amyotrophic lateral sclerosis and Parkinson’s disease.

Neuroscientists are developing a clearer picture than ever before of how the animal brain processes social information, from status and competitive advantage in a group to the calls and vocalizations of peers.